AKT1 and breast cancer: For instance, in breast cancer, the introduction of PI3K/Akt inhibitors such as a novel drug, econazole, has been able to counter the activation of PI3K/Akt pathway and, in turn, to prevent the resistance of tumour cells by exerting cytotoxic activity [150]; the treatment with phenybutyl isoselenocyanate (ISC-4) considerably slows down the activation of PI3K/Akt in a dose-dependent way [151].